Journal
JOURNAL OF PATHOLOGY
Volume 232, Issue 2, Pages 142-150Publisher
WILEY
DOI: 10.1002/path.4280
Keywords
triple-negative breast cancer; EGFR; FGFR; TP53; WEE1; AR; VEGFR; INPP4B; genomic instability; subtypes; TNBCtype; PHGDH; LDHB; INPP4B; PTEN; PIK3CA; TP53; basal-like; therapy
Funding
- Breast Cancer Specialized Program of Research Excellence (SPORE) [2P50CA098131]
- American Cancer Society [119807-PF-10-226-01-TBG]
- Susan G. Komen for the Cure [SAC110030, CCR13262005]
- NATIONAL CANCER INSTITUTE [P50CA098131] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that respond differentially to chemotherapy and targeted agents. The absence of high-frequency molecular alterations and a limited number of known biomarkers have limited the development of therapeutic strategies for the disease. Herein, we summarize the results of the first round of targeted therapy approaches in TNBC and discuss new preclinical strategies. Common themes emerge from the proposed strategies, such as the use of biomarkers to identify tumours with genomic instability, targeting adapted molecular states resulting from tumour suppressor loss, and targeting altered metabolic pathways. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available